Results 31 to 40 of about 13,446 (222)

Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study

Rheumatology and Therapy, 2020
Introduction The aim of this work is to investigate the improvement of physical function and its determinants in axial spondyloarthritis (SpA) patients treated with tumor necrosis factor (TNF) inhibitors in a real clinical practice setting.
Ennio Lubrano, Fabio Massimo Perrotta, Maria Manara, Salvatore D’Angelo, Roberta Ramonda, Leonardo Punzi, Olga Addimanda, Carlo Salvarani, Antonio Marchesoni   +8 more
doaj   +1 more source

Uveitis in Patients with Ankylosing Spondylitis

Journal of Nepal Health Research Council, 2021
Background: There is a close correlation between ankylosing spondylitis and uveitis, other less common ocular manifestations being episcleritis and scleritis.
Anjal Bisht, Samrat Shrestha, Priya Bajgai, Milan Khadka, Parimal Koirala, Kumud Bhattarai   +5 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, Accepted Article.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the CARRA, SPARTAN, and PRCSG Advisory Council   +9 more
wiley   +1 more source

Frequency of inflammatory back pain and sacroiliitis in Egyptian patients with rheumatoid arthritis

The Egyptian Journal of Radiology and Nuclear Medicine, 2019
Background The aim of this study is to determine the frequency of inflammatory back pain and associated ankylosing spondylitis in rheumatoid arthritis patients. Results Sacroiliitis was found in 22% of rheumatoid arthritis patients.
N.M.M. Osman, F. I. Mohamed, A. A. Hassan, S. R. Kamel, S. S. Ahmed   +4 more
doaj   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

Arthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Avaliação de marcadores inflamatórios e de metabolismo ósseo em pacientes com espondilite anquilosante [PDF]

, 2014
A Espondilite Anquilosante (EA) é uma doença inflamatória crônica auto-imune cuja patogênese ainda não está totalmente esclarecida, mas se sabe que além da inflamação, há a neoformação óssea, que determina importante dano estrutural.
Andrade, Kenia Rodrigues de
core  

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis [PDF]

, 2013
Technology: Infliximab and comparator biological such as adalimumab, etanercept, golimumab. Conditions: Ankylosing spondylitis (AS) Issue: Infliximab is registered to be used in patients with AS.
Péntek, Márta
core  

Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study [PDF]

, 2017
Background Patients with inflammatory bowel disease [IBD] often suffer from rheumatic manifestations, including inflammatory back disorders. The prevalence of these disorders late in the course of IBD is poorly investigated. The aim of this study was to
Småstuen, Milada Cvancarova, Negård, Anne, Høie, Ole Ingebreth, Moum, Bjørn, Lunder, Aida Kapic, Ossum, Alvilde Maria, Henriksen, Magne, Palm, Øyvind, Høivik, Marte Lie, Banitalebi, Hasan   +9 more
core   +3 more sources

Spondyloarthritis Preceding and Following Inflammatory Bowel Disease Diagnosis and Risk Factors: A Temporal Trends Analysis in a Population‐Based Cohort

Arthritis &Rheumatology, EarlyView.
Objective Spondyloarthritides (SpA) and inflammatory bowel disease (IBD) are immune‐mediated diseases with overlap in clinical and immunologic features. However, temporal correlation of SpA and IBD in individual patients and risk factors are not well characterized.
Manasi Agrawal, Christian N. Sørensen, Gry J. Poulsen, Bahar Moghaddam, Percio S. Gulko, Jean‐Frederic Colombel, Tine Jess   +6 more
wiley   +1 more source